| Literature DB >> 31558864 |
Jiong-Di Lu1, Feng Cao1, Yi-Xuan Ding1, Yu-Duo Wu2, Yu-Lin Guo1, Fei Li3.
Abstract
BACKGROUND: Acute pancreatitis (AP) is a common acute abdominal disease worldwide, and its incidence rate has increased annually. Approximately 20% of AP patients develop into necrotizing pancreatitis (NP), and 40% to 70% of NP patients have infectious complications, which usually indicate a worse prognosis. Infection is an important sign of complications in NP patients. AIM: To investigate the difference in infection time, infection site, and infectious strain in NP patients with infectious complications.Entities:
Keywords: Drug sensitivity test; Extrapancreatic infection; Necrotizing pancreatitis; Pathogenic bacteria
Mesh:
Substances:
Year: 2019 PMID: 31558864 PMCID: PMC6747290 DOI: 10.3748/wjg.v25.i34.5162
Source DB: PubMed Journal: World J Gastroenterol ISSN: 1007-9327 Impact factor: 5.742
Comparison of baseline demographic and clinical characteristics between the infection group and non-infection group
| Age (yr) | 49.5 ± 15.7 | 50.3 ± 15.5 | 46.6 ± 16.7 | 0.173 |
| Male | 140 | 112 | 28 | 0.801 |
| Etiology | 0.898 | |||
| Biliary | 109 | 88 | 21 | |
| Alcohol | 10 | 7 | 3 | |
| Hyperlipemia | 67 | 52 | 15 | |
| ERCP | 6 | 5 | 1 | |
| Others | 13 | 11 | 2 | |
| Referral time | 24 (0-300) | 30 (0-300) | 2.5 (0-180) | 0.013 |
| CTSI | 4 (2-10) | 6 (2-10) | 4 (2-8) | 0.127 |
| Persistent OF | 50 | 49 | 1 | 0.005 |
| Need for any intervention | 120 | 113 | 7 | < 0.001 |
| Death | 20 | 18 | 2 | 0.191 |
| TPN | 17 (0-163) | 18 (0-163) | 10 (0-47) | < 0.001 |
| EN | 1 (0-112) | 2 (0-112) | 0 (0-34) | 0.004 |
| Length of hospital stay(d) | 29 (0-172) | 32 (0-172) | 19 (5-48) | < 0.001 |
| Length of stay ICU stay | 11 (0-117) | 13 (0-28) | 7 (0-117) | 0.004 |
| Necrosis degree | 0.018 | |||
| < 30% | 40 | 26 | 14 | |
| 30%-50% | 80 | 65 | 15 | |
| > 50% | 85 | 72 | 13 |
P < 0.05,
P < 0.01,
P < 0.001. ERCP: Endoscopic retrograde cholangio pancreatography; CTSI: Computer tomography severity scan; OF: Organ failure; TPN: Total parenteral nutrition; EN: Enteral nutrition; ICU: Intensive care unit.
Microbiological profile of organisms in infected patients
| Gram-negative | ||
| 34 | 32 | |
| 22 | 22 | |
| 34 | 20 | |
| 30 | 16 | |
| Gram-positive | ||
| 5 | 32 | |
| 18 | 30 | |
| 5 | 19 | |
| 5 | 8 | |
| Fungal | ||
| 3 | 19 | |
| 0 | 12 | |
| 0 | 12 | |
| 1 | 9 |
INP: Infectious necrotizing pancreatitis; E. coli: Escherichia coli; P. aeruginosa: Pseudomonas aeruginosa; A. baumannii: Acinetobacter baumannii; K. pneumoniae: Klebsiella pneumoniae; E. faecium: Enterococcus faecium; S. epidermidis: Staphylococcus epidermidis; S. aureus: Staphylococcus aureus; E. faecalis: Enterococcus faecalis; C. albicans: Candida albicans; C. parapsilosis: Candida parapsilosis; C. tropicalis: Candida tropicalis; C. glabrata: Candida glabrata.
Drug sensitivity of Gram-negative bacteria in infected patients
| Antibiotic | ||||||||
| MDR bacteria | 9/34 | 9/34 | 16/22 | 15/30 | 8/32 | 4/20 | 17/22 | 11/16 |
| ESBL +: | — | 14/34 | — | 6/30 | — | 10/20 | — | 2/16 |
| Penicillins | ||||||||
| Ampicillin | 0/34 | 8/34 | 0/22 | 1/30 | 0/32 | 4/20 | 1/22 | 0/16 |
| Piperacillin | 12/34 | 4/34 | 0/22 | 3/30 | 14/32 | 4/20 | 1/22 | 0/16 |
| Enzymatic penicillins | ||||||||
| Piperacillin/tazobactam | 13/34 | 10/34 | 4/22 | 8/30 | 19/32 | 11/20 | 1/22 | 4/16 |
| Cefoperazone/sulbactam | 8/34 | 0/34 | 4/22 | 0/30 | 9/32 | 0/20 | 4/22 | 0/16 |
| Ampicillin/sulbactam | 0/34 | 4/34 | 0/22 | 4/30 | 0/32 | 6/20 | 4/22 | 0/16 |
| quinolones | ||||||||
| Levofloxacin | 21/34 | 11/34 | 3/22 | 11/30 | 17/32 | 6/20 | 3/22 | 3/16 |
| First- and second-generation cephalosporins | ||||||||
| Cefoxitin | 0/34 | 0/34 | 0/22 | 0/30 | 0/32 | 0/20 | 0/22 | 0/16 |
| Cefuroxime | 0/34 | 0/34 | 0/22 | 0/30 | 0/32 | 0/20 | 0/22 | 0/16 |
| Third- and fourth-generation cephalosporins | ||||||||
| Ceftazidime | 14/34 | 13/34 | 3/22 | 7/30 | 16/32 | 11/20 | 3/22 | 2/16 |
| Cefepime | 17/34 | 12/34 | 3/22 | 10/30 | 15/32 | 11/20 | 3/22 | 3/16 |
| Carbapenems | ||||||||
| Imipenem | 10/34 | 21/34 | 2/22 | 11/30 | 10/32 | 12/20 | 3/22 | 2/16 |
| Meropenem | 10/34 | 11/34 | 3/22 | 6/30 | 9/32 | 6/20 | 3/22 | 2/16 |
| Sulfonamides | ||||||||
| Compound trimethoprim | 1/34 | 14/34 | 9/22 | 14/30 | 0/32 | 10/20 | 8/22 | 9/16 |
| Tetracycline | ||||||||
| Tigecycline | 1/34 | 1/34 | 17/22 | 13/30 | 0/32 | 2/20 | 18/22 | 9/16 |
| Minocycline | — | — | 9/22 | — | 0/32 | — | 10/22 | — |
MDR: Multidrug-resistant; ESBL: Extended-spectrum β-lactamases; E. coli: Escherichia coli; P. aeruginosa: Pseudomonas aeruginosa; A. baumannii: Acinetobacter baumannii; K. pneumoniae: Klebsiella pneumoniae.
Drug sensitivity of Gram-positive bacteria in infected patients
| Antibiotic | ||||||||
| MDR bacteria | 5/18 | 0/5 | 2/5 | 3/6 | 4/30 | 1/32 | 3/8 | 0/5 |
| ESBL +: | — | 3/5 | 3/5 | — | — | 12/32 | 3/8 | — |
| Penicillins | ||||||||
| Ampicillin | 2/18 | 0/5 | 0/5 | 3/6 | 1/30 | 0/32 | 0/8 | 3/5 |
| Penicillin G | 0/18 | 0/5 | 0/5 | 1/6 | 0/30 | 0/32 | 0/8 | 3/5 |
| quinolones | ||||||||
| Ciprofloxacin | 1/18 | 0/5 | 0/5 | 1/6 | 0/30 | 8/32 | 3/8 | 3/5 |
| Levofloxacin | 2/18 | 0/5 | 0/5 | 1/6 | 1/30 | 8/32 | 3/8 | 3/5 |
| Moxifloxacin | 1/18 | 2/5 | 0/5 | 1/6 | 1/30 | 21/32 | 3/8 | 3/5 |
| Macrolactones | ||||||||
| Linezolid | 14/18 | 5/5 | 4/5 | 5/6 | 25/30 | 31/32 | 8/8 | 4/5 |
| Tetracycline | ||||||||
| Tigecycline | 17/18 | 5/5 | 5/5 | 5/6 | 27/30 | 32/32 | 8/8 | 5/5 |
| Sulfonamides | ||||||||
| Compound trimethoprim | 1/18 | 1/5 | 4/5 | 0/6 | 2/30 | 9/32 | 6/8 | 2/5 |
| Polypeptides | ||||||||
| Vancomycin | 11/18 | 5/5 | 5/5 | 6/6 | 25/30 | 31/32 | 8/8 | 5/5 |
MDR: Multidrug-resistant; ESBL: Extended-spectrum β-lactamase; E. faecium: Enterococcus faecium; S. epidermidis: Staphylococcus epidermidis; S. aureus: Staphylococcus aureus; E. faecalis: Enterococcus faecalis.
Figure 1Time and location distribution of extrapancreatic infection. In the early stage of necrotizing pancreatitis (NP), the most common sites of extrapancreatic infection were the blood, respiratory tract, and abdominal cavity. In the late stage of NP, the most common sites of extrapancreatic infection were the blood, respiratory tract, and urinary tract. NP: Necrotizing pancreatitis.
Multivariable analysis for independent predictors of mortality
| Persistent OF | 5.37 (3.785-7.618) | < 0.001 | 0.012 (0.001-0.101) | < 0.001 |
| MDR organism (s) | 2.445 (1.554-3.848) | 0.001 | 0.134 (0.028-0.633) | 0.011 |
| Fungal infection | 2.719 (1.498-4.936) | 0.002 | 0.657 (0.156-2.770) | 0.567 |
| Prophylactic antibiotic | 0.974 (0.783-1.210) | 0.8 | 0.534 (0.095-2.989) | 0.475 |
| INP | 1.151 (0.802-1.651) | 0.48 | 0.277 (0.024-3.234) | 0.306 |
| Extrapancreatic infection | 1.383 (1.124-1.704) | 0.031 | 0.627 (0.042-9.273) | 0.734 |
| Referred patients | 1.102 (0.986-1.232) | 0.25 | 0.524 (0.041-6.655) | 0.619 |
| Operation | 0.789 (0.497-1.255) | 0.262 | 10.533 (1.052-105.491) | 0.045 |
| Complication | 2.921 (1.304-6.540) | 0.011 | 0.892 (0.191-4.162) | 0.885 |
P < 0.05,
P < 0.01,
P < 0.001. OF: Organ failure; INP: Infectious necrotizing pancreatitis; TPN: Total parenteral nutrition; EN: Enteral nutrition; CI: Confidence interval; OR: Odds ratio; MDR: Multidrug-resistant.